Invest Now
Samco securities limited
Samco Star Rating Ads

Suven Pharmaceuticals Ltd

₹ 1,202 +11.25 (0.94%)

Updated on 09-10-2024 2:54 PM

Stock Rating

Pros 6

 

Cons 3

Price Performance

  • Day's Low
  • ₹1,167.70
  • Day's High
  • ₹1,219.80
₹ 1,202
  • 52-w low
  • ₹541
  • 52-w high
  • ₹1,287.90
1,202
  • Day's open
    ₹1,197
  • Previous close
    ₹1,190.75
  • VWAP
    ₹1,180.21
  • Lower price band
    ₹952.6
  • Upper price band
    ₹1,428.90

Today's Market Action

The last traded share price of Suven Pharmaceuticals Ltd was 1,202 up by 0.94% on the NSE. Its last traded stock price on BSE was 1,202.75 up by 0.76%. The total volume of shares on NSE and BSE combined was 486,290 shares. Its total combined turnover was Rs 57.40 crores.

Medium and Long Term Market Action

Suven Pharmaceuticals Ltd hit a 52-week high of 1,287.90 on 23-09-2024 and a 52-week low of 541 on 26-10-2023. The stock price of Suven Pharmaceuticals Ltd is down by -1% over the last one month. It is up by 112.74% over the last one year. Don't forget to check the full stock price history in the table below.

Fundamentals

  • Market Cap (Cr): 30312

  • Book Value (₹):

  • Stock P/E:

  • Revenue (Cr):

  • Total Debt (Cr):

  • Face Value (₹):

  • Roce (%):

  • ROE (%):

  • Earnings (Cr):

  • Promoter’s Holdings (%):

  • EPS (₹):

  • Debt to Equity:

  • Dividend Yield (%):

  • Cash (Cr):

Mutual fund holdings and trends

FUND NAME Quantity Monthly Change (Qty)

Shareholding Pattern

Similar Stocks

Company Price Market Cap (Cr) P/E

About

Data not available.

FAQ's

What is Share Price of Suven Pharmaceuticals Ltd?

What is the Market Cap of Suven Pharmaceuticals Ltd?

What is PE Ratio of Suven Pharmaceuticals Ltd?

What is PB Ratio of Suven Pharmaceuticals Ltd?

What is the CAGR of Suven Pharmaceuticals Ltd?

How to Buy Suven Pharmaceuticals Ltd Share?

(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

Pros

  • Momentum Strength
    The stock is currently exhibiting strong momentum, & is showing consistent strong relative strength.
  • Above Average Sustainable RoE
    The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
  • Great Cash Conversion of Profits
    The business has a great cash conversion ratio since it is able to convert a signifant portion of operating earnings of 76.50% into operating cash flow. This implies a great working capital cycle and large cash flows for either funding growth or dividends. This shall positively impact shareholder returns.
  • Secular & Predictable Business
    The company business as a relatively secular business with predictable earnings and cash flows. The predictability of the business will result in lower volatility of price and shareholder returns.
  • High Pricing Power
    The business enjoys a relatively high pricing power and is able to withstand competitive pressure which works as a great moat for equity shareholders of the company.
  • Zero Debt
    The company has almost nil to negligible debt to equity ratio of 0.03. Considering the fact that the business is debt free, equity shareholders shall carry lower risk of holding the stock.

Cons

  • Capital Intensive Business
    The company operates an extremely capital intensive business with a low Asset turnover ratio of 1.38. A low asset turnover ratio negatively impacts RoE and reduces shareholder returns. Also due to the capital intensive nature of business, growth of the business would need to be funded either via increasing borrowings or diluting shareholders, both of which shall negatively impact shareholder value and returns.
  • Poor Working Capital Cycle
    The company has a very poor working capital cycle of 114 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.
  • Negative Margin of Safety
    The relative margin of safety of investing in the company is low due to a recent sharp run up in stock prices.

Valuation Analysis

Margin of safety
(09/10/2024)
Stock Valuation
Red line
80
0.00%
0.00% People are bullish about Suven Pharmaceuticals Ltd
100.00%
100.00 % People are bearish about Suven Pharmaceuticals Ltd

What is your opinion about this Stock?

Historical Data

Samco Star Rating Ads

Suven Pharmaceuticals Ltd

₹ 1,202 +11.25 (0.94%)

Brokerage & Taxes at Samco

Brokerage & Taxes at Other traditional broker

Potential Brokerage Savings with Samco ₹ 49.62()

Top Gainers (NIFTY 50)

Stock Name Change %

    Top Losers (NIFTY 50)

    Stock Name Change %

      ×

      Filing Complaints on SCORES

      Easy & quick Easy & quick

      1. Register on SCORES portal

      2. Mandatory details for filling complaints on SCORES

      Name | PAN | Address | Mobile | Number | E-mail ID

      3. Benefits

      Effective Communication

      Speedy redressal of the grievances

      Website Icon